Logo

Corixa To Acquire All Shares of GenQuest

Dec 18, 1998
Premium

SEATTLE--Corixa, a development-stage biotechnology company founded here in 1994, announced that it will purchase the privately held, oncology-based functional genomics company GenQuest for $11.8 million--$4.5 million in cash. Corixa currently holds approximately 17 percent of the company's outstanding capital stock. GenQuest will consolidate its operations here and be fully integrated into Corixa. The combined entity will have approximately 100 scientific employees dedicated to discovery and early development of vaccines.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.